CURE:AU:AU-ETFS S&P Biotech ETF (AUD)

ETF | Others |

Last Closing

USD 48.66

Change

+0.20 (+0.41)%

Market Cap

USD 0.04B

Volume

1.37K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

-1.79 (-1.73%)

USD 16.05B
VGS:AU Vanguard MSCI International Sh..

-0.08 (-0.06%)

USD 8.59B
IVV:AU iShares Core S&P 500 AUD

+0.22 (+0.40%)

USD 8.26B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.02 (+0.04%)

USD 6.31B
IOZ:AU Ishares Core S&P/Asx 200

-0.15 (-0.45%)

USD 6.10B
STW:AU SPDR® S&P/ASX 200 Fund

-0.53 (-0.71%)

USD 5.68B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.17 (+0.42%)

USD 4.86B
NDQ:AU Betashares Nasdaq 100

+0.18 (+0.42%)

USD 4.83B
A200:AU BetaShares Australia 200

-2.27 (-1.63%)

USD 4.72B
VTS:AU Vanguard US Total Market Share..

+1.96 (+0.48%)

USD 4.70B

ETFs Containing CURE:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.29% 45% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.29% 34% F 59% D-
Trailing 12 Months  
Capital Gain 27.72% 86% B+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.72% 84% B 76% C+
Trailing 5 Years  
Capital Gain 2.70% 37% F 59% D-
Dividend Return 13.26% 59% D- 43% F
Total Return 15.96% 36% F 59% D-
Average Annual (5 Year Horizon)  
Capital Gain -2.67% N/A N/A 36% F
Dividend Return -0.28% N/A N/A 37% F
Total Return 2.39% N/A N/A 46% F
Risk Return Profile  
Volatility (Standard Deviation) 21.75% N/A N/A 72% C
Risk Adjusted Return -1.30% N/A N/A 37% F
Market Capitalization 0.04B 10% F 46% F

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.